

# Steven Joffe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714459/publications.pdf>

Version: 2024-02-01

213  
papers

12,764  
citations

28242

55  
h-index

26591

107  
g-index

219  
all docs

219  
docs citations

219  
times ranked

17417  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2014, 370, 311-321.	13.9	1,387
2	A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease. <i>New England Journal of Medicine</i> , 2013, 369, 341-350.	13.9	1,005
3	Quality of informed consent in cancer clinical trials: a cross-sectional survey. <i>Lancet, The</i> , 2001, 358, 1772-1777.	6.3	578
4	Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. <i>Nature Medicine</i> , 2014, 20, 682-688.	15.2	508
5	Clinical Trials and Medical Care: Defining the Therapeutic Misconception. <i>PLoS Medicine</i> , 2007, 4, e324.	3.9	376
6	Quality of Informed Consent: a New Measure of Understanding Among Research Subjects. <i>Journal of the National Cancer Institute</i> , 2001, 93, 139-147.	3.0	349
7	Return of Genomic Results to Research Participants: The Floor, the Ceiling, and the Choices In Between. <i>American Journal of Human Genetics</i> , 2014, 94, 818-826.	2.6	342
8	Comparison of outcomes in cancer patients treated within and outside clinical trials: conceptual framework and structured review. <i>Lancet, The</i> , 2004, 363, 263-270.	6.3	336
9	Actionable exomic incidental findings in 6503 participants: challenges of variant classification. <i>Genome Research</i> , 2015, 25, 305-315.	2.4	313
10	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2013, 31, 2437-2449.	0.8	223
11	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1498-1501.	2.0	210
12	Cost-effectiveness of Respiratory Syncytial Virus Prophylaxis Among Preterm Infants. <i>Pediatrics</i> , 1999, 104, 419-427.	1.0	191
13	Reframing Consent for Clinical Research: A Function-Based Approach. <i>American Journal of Bioethics</i> , 2017, 17, 3-11.	0.5	176
14	Equipoise and the Dilemma of Randomized Clinical Trials. <i>New England Journal of Medicine</i> , 2011, 364, 476-480.	13.9	165
15	A Randomized Study of How Physicians Interpret Research Funding Disclosures. <i>New England Journal of Medicine</i> , 2012, 367, 1119-1127.	13.9	165
16	Ethics and Genomic Incidental Findings. <i>Science</i> , 2013, 340, 1047-1048.	6.0	160
17	Rehospitalization for Respiratory Syncytial Virus Among Premature Infants. <i>Pediatrics</i> , 1999, 104, 894-899.	1.0	142
18	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016, 98, 1051-1066.	2.6	137

#	ARTICLE	IF	CITATIONS
19	Patients' Views on Financial Conflicts of Interest in Cancer Research Trials. <i>New England Journal of Medicine</i> , 2006, 355, 2330-2337.	13.9	131
20	Rehospitalization in the First Two Weeks After Discharge From the Neonatal Intensive Care Unit. <i>Pediatrics</i> , 1999, 104, e2-e2.	1.0	125
21	Informed Consent for Medical Treatment and Research: A Review. <i>Oncologist</i> , 2005, 10, 636-641.	1.9	125
22	The National Cancer Institute's American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and Recommendations. <i>Journal of Oncology Practice</i> , 2013, 9, 267-276.	2.5	121
23	Sharing of clinical trial data among trialists: a cross sectional survey. <i>BMJ</i> , 2012, 345, e7570-e7570.	3.0	112
24	Bench to Bedside: Mapping the Moral Terrain of Clinical Research. <i>Hastings Center Report</i> , 2008, 38, 30-42.	0.7	110
25	What do patients value in their hospital care? An empirical perspective on autonomy centred bioethics. <i>Journal of Medical Ethics</i> , 2003, 29, 103-108.	1.0	108
26	Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. <i>Genetics in Medicine</i> , 2016, 18, 1011-1019.	1.1	108
27	The Impact of Disclosing Financial Ties in Research and Clinical Care. <i>Archives of Internal Medicine</i> , 2010, 170, 675.	4.3	107
28	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1116-1123.	2.0	104
29	Communicating About Prognosis: Ethical Responsibilities of Pediatricians and Parents. <i>Pediatrics</i> , 2014, 133, S24-S30.	1.0	103
30	The clinical imperative for inclusivity: Race, ethnicity, and ancestry (REA) in genomics. <i>Human Mutation</i> , 2018, 39, 1713-1720.	1.1	102
31	Altruism among participants in cancer clinical trials. <i>Clinical Trials</i> , 2011, 8, 616-623.	0.7	101
32	Incidental Findings in Human Subjects Research: What Do Investigators Owe Research Participants?. <i>Journal of Law, Medicine and Ethics</i> , 2008, 36, 271-279.	0.4	96
33	Parents' Views of Cancer-Directed Therapy for Children With No Realistic Chance for Cure. <i>Journal of Clinical Oncology</i> , 2008, 26, 4759-4764.	0.8	95
34	Patient Perspectives on the Learning Health System: The Importance of Trust and Shared Decision Making. <i>American Journal of Bioethics</i> , 2015, 15, 4-17.	0.5	94
35	Views of American Oncologists About the Purposes of Clinical Trials. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1847-1853.	3.0	93
36	Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest. <i>JAMA Internal Medicine</i> , 2017, 177, 344.	2.6	93

#	ARTICLE	IF	CITATIONS
37	A taxonomy of medical uncertainties in clinical genome sequencing. <i>Genetics in Medicine</i> , 2017, 19, 918-925.	1.1	91
38	Addressing the Ethical Challenges in Genetic Testing and Sequencing of Children. <i>American Journal of Bioethics</i> , 2014, 14, 3-9.	0.5	90
39	Attitudes Toward Risk and Informed Consent for Research on Medical Practices. <i>Annals of Internal Medicine</i> , 2015, 162, 690-696.	2.0	87
40	Can RESEARCH and CARE Be Ethically Integrated?. <i>Hastings Center Report</i> , 2011, 41, 37-46.	0.7	85
41	Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. <i>Blood</i> , 2004, 104, 2194-2200.	0.6	84
42	Increasing response rates from physicians in oncology research: a structured literature review and data from a recent physician survey. <i>British Journal of Cancer</i> , 2012, 106, 1021-1026.	2.9	83
43	The New Age of Patient Autonomy. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1973.	3.8	82
44	Involving children with cancer in decision-making about research participation. <i>Journal of Pediatrics</i> , 2006, 149, 862-868.e1.	0.9	81
45	Benefit in phase 1 oncology trials: therapeutic misconception or reasonable treatment option?. <i>Clinical Trials</i> , 2008, 5, 617-623.	0.7	76
46	Rethinking Risk-Benefit Assessment for Phase I Cancer Trials. <i>Journal of Clinical Oncology</i> , 2006, 24, 2987-2990.	0.8	75
47	Children are not small adults: Documentation of assent for research involving children. <i>Journal of Pediatrics</i> , 2006, 149, S31-S33.	0.9	71
48	Private Cord Blood Banking: Experiences and Views of Pediatric Hematopoietic Cell Transplantation Physicians. <i>Pediatrics</i> , 2009, 123, 1011-1017.	1.0	65
49	Reputation and Precedent in the Bevacizumab Decision. <i>New England Journal of Medicine</i> , 2011, 365, e3.	13.9	63
50	The Challenge of Informed Consent and Return of Results in Translational Genomics: Empirical Analysis and Recommendations. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 344-355.	0.4	63
51	Evaluating Novel Therapies During the Ebola Epidemic. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1299.	3.8	63
52	Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage. <i>PLoS Medicine</i> , 2017, 14, e1002190.	3.9	62
53	Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants. <i>Journal of the National Cancer Institute</i> , 2004, 96, 629-632.	3.0	61
54	Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. <i>Genetics in Medicine</i> , 2014, 16, 727-735.	1.1	60

#	ARTICLE	IF	CITATIONS
55	Limits to research risks. <i>Journal of Medical Ethics</i> , 2009, 35, 445-449.	1.0	59
56	Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement. <i>Journal of Clinical Oncology</i> , 2018, 36, 3331-3339.	0.8	58
57	Evaluating the Therapeutic Misconception. <i>Kennedy Institute of Ethics Journal</i> , 2006, 16, 353-366.	0.3	57
58	The OHRP and SUPPORT. <i>New England Journal of Medicine</i> , 2013, 368, e36.	13.9	57
59	Ethics Consultation in Children's Hospitals: Results From a Survey of Pediatric Clinical Ethicists. <i>Pediatrics</i> , 2010, 125, 742-746.	1.0	53
60	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 861-873.	2.0	53
61	Individual Physician Practice Variation in Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 2162-2170.	0.8	52
62	Variation in Supportive Care Practices in Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1231-1238.	2.0	51
63	Including all voices in international data-sharing governance. <i>Human Genomics</i> , 2018, 12, 13.	1.4	50
64	Guidelines for return of research results from pediatric genomic studies: deliberations of the Boston Children's Hospital Gene Partnership Informed Cohort Oversight Board. <i>Genetics in Medicine</i> , 2014, 16, 547-552.	1.1	49
65	Parental Decision-Making Preferences in Neonatal Intensive Care. <i>Journal of Pediatrics</i> , 2016, 179, 36-41.e3.	0.9	49
66	Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. <i>Genetics in Medicine</i> , 2017, 19, 787-795.	1.1	46
67	Pediatricians' Reports of Their Education in Ethics. <i>JAMA Pediatrics</i> , 2008, 162, 368.	3.6	45
68	National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1308-1314.	2.0	45
69	Experiences and attitudes of genome investigators regarding return of individual genetic test results. <i>Genetics in Medicine</i> , 2013, 15, 882-887.	1.1	44
70	When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. <i>American Journal of Bioethics</i> , 2019, 19, 11-18.	0.5	44
71	Rethink "Affirmative Agreement," but Abandon "Assent". <i>American Journal of Bioethics</i> , 2003, 3, 9-11.	0.5	43
72	Relationship of Race/Ethnicity and Survival after Single Umbilical Cord Blood Transplantation for Adults and Children with Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 903-912.	2.0	43

#	ARTICLE	IF	CITATIONS
73	Survival Improvements in Adolescents and Young Adults after Myeloablative Allogeneic Transplantation for Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 829-836.	2.0	43
74	Hospital Length of Stay in the First 100 Days after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia in Remission: Comparison among Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1819-1827.	2.0	43
75	Direct-to-Consumer Advertising in Oncology. <i>Oncologist</i> , 2006, 11, 217-226.	1.9	42
76	Paying Patients for Their Tissue: The Legacy of Henrietta Lacks. <i>Science</i> , 2012, 337, 37-38.	6.0	41
77	Chemotherapy Drug Shortages in Pediatric Oncology: A Consensus Statement. <i>Pediatrics</i> , 2014, 133, e716-e724.	1.0	41
78	“Entering a clinical trial: Is it right for you?” <i>Cancer</i> , 2012, 118, 1877-1883.	2.0	39
79	Gender and Byline Placement of Co-first Authors in Clinical and Basic Science Journals With High Impact Factors. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 610.	3.8	39
80	Federal Right-to-Try Legislation “Threatening the FDA’s Public Health Mission. <i>New England Journal of Medicine</i> , 2018, 378, 695-697.	13.9	39
81	Considerations About Hastening Death Among Parents of Children Who Die of Cancer. <i>JAMA Pediatrics</i> , 2010, 164, 231.	3.6	38
82	Characteristics Associated With Preferences for Parent-Centered Decision Making in Neonatal Intensive Care. <i>JAMA Pediatrics</i> , 2018, 172, 461.	3.3	37
83	The first step to integrating the child’s voice in adverse event reporting in oncology trials: A content validation study among pediatric oncology clinicians. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1231-1236.	0.8	36
84	Clinical Trials Infrastructure as a Quality Improvement Intervention in Low- and Middle-Income Countries. <i>American Journal of Bioethics</i> , 2016, 16, 3-11.	0.5	35
85	Frequency, Type, and Monetary Value of Financial Conflicts of Interest in Cancer Clinical Research. <i>Journal of Clinical Oncology</i> , 2007, 25, 3609-3614.	0.8	33
86	Advance Care Planning in Patients Undergoing Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 65-73.	2.0	33
87	Justifying Clinical Nudges. <i>Hastings Center Report</i> , 2017, 47, 32-38.	0.7	33
88	Transplant center characteristics and survival after allogeneic hematopoietic cell transplantation in adults. <i>Bone Marrow Transplantation</i> , 2020, 55, 906-917.	1.3	33
89	Gatekeepers for pragmatic clinical trials. <i>Clinical Trials</i> , 2015, 12, 442-448.	0.7	32
90	Relationships Between Authorship Contributions and Authors’ Industry Financial Ties Among Oncology Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1316-1321.	0.8	31

#	ARTICLE	IF	CITATIONS
91	Recommendations for the Return of Research Results to Study Participants and Guardians: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2012, 30, 4573-4579.	0.8	31
92	Implications of Zero Suicide for Suicide Prevention Research. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1633.	3.8	30
93	Equipoise: asking the right questions for clinical trial design. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 230-235.	12.5	28
94	Clinical Trial Participation among Ethnic/Racial Minority and Majority Patients with Advanced Cancer: What Factors Most Influence Enrollment?. <i>Journal of Palliative Medicine</i> , 2013, 16, 256-262.	0.6	28
95	Phase 1 oncology trials and informed consent. <i>Journal of Medical Ethics</i> , 2013, 39, 761-764.	1.0	28
96	Professionally Responsible Disclosure of Genomic Sequencing Results in Pediatric Practice. <i>Pediatrics</i> , 2015, 136, e974-e982.	1.0	28
97	An Ethical Framework for Allocating Scarce Life-Saving Chemotherapy and Supportive Care Drugs for Childhood Cancer. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv392.	3.0	28
98	Generalizability of Trial Results to Elderly Medicare Patients With Advanced Solid Tumors (Alliance) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.0	27
99	Education in Professionalism: Results from a Survey of Pediatric Residency Program Directors. <i>Journal of Graduate Medical Education</i> , 2012, 4, 101-105.	0.6	25
100	Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey. <i>Trials</i> , 2014, 15, 384.	0.7	24
101	Satisfaction of the uncertainty principle in cancer clinical trials: retrospective cohort analysis. <i>BMJ: British Medical Journal</i> , 2004, 328, 1463.	2.4	22
102	Clinical research: Should patients pay to play?. <i>Science Translational Medicine</i> , 2015, 7, 298ps16.	5.8	22
103	Ethical considerations in genomic testing for hematologic disorders. <i>Blood</i> , 2017, 130, 460-465.	0.6	22
104	IRB practices and policies regarding the secondary research use of biospecimens. <i>BMC Medical Ethics</i> , 2015, 16, 32.	1.0	21
105	Perceived Utility of Genomic Sequencing: Qualitative Analysis and Synthesis of a Conceptual Model to Inform Patient-Centered Instrument Development. <i>Patient</i> , 2022, 15, 317-328.	1.1	21
106	Outcomes of informed consent among parents of children in cancer clinical trials. <i>Pediatric Blood and Cancer</i> , 2011, 57, 998-1004.	0.8	20
107	Returning genetic research results: study type matters. <i>Personalized Medicine</i> , 2013, 10, 27-34.	0.8	20
108	Informed Consent and the Role of the Treating Physician. <i>New England Journal of Medicine</i> , 2018, 378, 2433-2438.	13.9	20

#	ARTICLE	IF	CITATIONS
109	Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. <i>Journal of Clinical Oncology</i> , 2008, 26, 5994-6000.	0.8	19
110	Justification and authority in institutional review board decision letters. <i>Social Science and Medicine</i> , 2017, 194, 25-33.	1.8	19
111	Data and Safety Monitoring of COVID-19 Vaccine Clinical Trials. <i>Journal of Infectious Diseases</i> , 2021, 224, 1995-2000.	1.9	19
112	491-503.	0.9	18
113	Pediatric oncology research in low income countries: Ethical concepts and challenges. <i>Pediatric Blood and Cancer</i> , 2012, 58, 492-497.	0.8	18
114	A Prescription for Ethical Learning. <i>Hastings Center Report</i> , 2013, 43, S28-S29.	0.7	18
115	Inflammatory Bowel Disease Associated With Immune Thrombocytopenic Purpura in Children. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2001, 33, 582-587.	0.9	17
116	When Participants in Genomic Research Grow Up: Contact and Consent at the Age of Majority. <i>Journal of Pediatrics</i> , 2016, 168, 226-231.e1.	0.9	17
117	Patient and physician views about protocolized dialysis treatment in randomized trials and clinical care. <i>AJOB Empirical Bioethics</i> , 2016, 7, 106-115.	0.8	16
118	Is Blood Thicker Than Water?. <i>JAMA Pediatrics</i> , 2009, 163, 413.	3.6	15
119	Development of a Test of Residents' Ethics Knowledge for Pediatrics (TREK-P). <i>Journal of Graduate Medical Education</i> , 2012, 4, 242-245.	0.6	15
120	The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. <i>Personalized Medicine</i> , 2017, 14, 37-50.	0.8	15
121	Compact versus Contract " Industry Sponsors' Obligations to Their Research Subjects. <i>New England Journal of Medicine</i> , 2007, 356, 2737-2743.	13.9	14
122	A Unique Researcher Identifier for the Physician Payments Sunshine Act. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2007-8.	3.8	14
123	Balancing Access and Evaluation in the Approval of New Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2345.	3.8	14
124	Commentary on Hey and Kimmelman. <i>Clinical Trials</i> , 2015, 12, 116-118.	0.7	14
125	Ethics knowledge of recent paediatric residency graduates: the role of residency ethics curricula. <i>Journal of Medical Ethics</i> , 2016, 42, 809-814.	1.0	14
126	The Ethics of Infection Challenges in Primates. <i>Hastings Center Report</i> , 2016, 46, 20-26.	0.7	14



#	ARTICLE	IF	CITATIONS
127	Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2145-2151.	2.0	14
128	Harmonization of Ethics Policies in Pediatric Research. <i>Journal of Law, Medicine and Ethics</i> , 2011, 39, 70-78.	0.4	13
129	Protecting the rights and interests of pediatric stem cell donors. <i>Pediatric Blood and Cancer</i> , 2011, 56, 517-519.	0.8	13
130	Discontinuing Bevacizumab in Patients with Glioblastoma: An Ethical Analysis. <i>Oncologist</i> , 2011, 16, 1435-1439.	1.9	13
131	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1815-1822.	2.0	13
132	A Systematic Review of State and Manufacturer Physician Payment Disclosure Websites: Implications for Implementation of the Sunshine Act. <i>Journal of Law, Medicine and Ethics</i> , 2014, 42, 208-219.	0.4	12
133	Promoting Informed Decision Making for Comparative Effectiveness Randomized Trials. <i>JAMA Pediatrics</i> , 2015, 169, 803.	3.3	12
134	Are hybrid umbilical cord blood banks really the best of both worlds?. <i>Journal of Medical Ethics</i> , 2015, 41, 272-275.	1.0	12
135	The benefit sharing vision of H3Africa. <i>Developing World Bioethics</i> , 2018, 18, 165-170.	0.6	12
136	Concurrent and Overlapping Surgery. <i>Spine</i> , 2019, 44, 53-59.	1.0	12
137	Influence of Genetic Information on Neonatologists'™ Decisions: A Psychological Experiment. <i>Pediatrics</i> , 2022, 149, .	1.0	12
138	Ethics of Cancer Clinical Trials in Low-Resource Settings. <i>Journal of Clinical Oncology</i> , 2014, 32, 3192-3196.	0.8	11
139	Chemotherapy Parity Laws. <i>JAMA Internal Medicine</i> , 2014, 174, 1721.	2.6	11
140	Pediatric reporting of genomic results study (PROGRESS): a mixed-methods, longitudinal, observational cohort study protocol to explore disclosure of actionable adult- and pediatric-onset genomic variants to minors and their parents. <i>BMC Pediatrics</i> , 2020, 20, 222.	0.7	11
141	CNS Relapse of Acute Myelogenous Leukemia Masquerading as Pseudotumor Cerebri. <i>Pediatric Neurology</i> , 2008, 39, 355-357.	1.0	10
142	Bone Marrow Donation Between Siblings Living in Different Families. <i>Pediatrics</i> , 2011, 127, 158-162.	1.0	10
143	Ethical Issues for Control-Arm Patients After Revelation of Benefits of Experimental Therapy: A Framework Modeled in Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 641-646.	0.8	9
144	Reply to S. Gupta et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1414-1414.	0.8	9

#	ARTICLE	IF	CITATIONS
145	Consent insufficient for data release. <i>Science</i> , 2019, 364, 445-446.	6.0	9
146	Altruistic Discourse and Therapeutic Misconception in Research Informed Consent. <i>American Journal of Bioethics</i> , 2006, 6, 53-54.	0.5	8
147	Revolution or Reform in Human Subjects Research Oversight. <i>Journal of Law, Medicine and Ethics</i> , 2012, 40, 922-929.	0.4	8
148	Consent for clinical genome sequencing: considerations from the Clinical Sequencing Exploratory Research Consortium. <i>Personalized Medicine</i> , 2019, 16, 325-333.	0.8	8
149	Allocating scarce life-saving resources: the proper role of age. <i>Journal of Medical Ethics</i> , 2021, 47, 836-838.	1.0	8
150	Survival Improvements Following Myeloablative Allogeneic Hematopoietic Cell Transplantation For Acute Lymphoblastic Leukemia In Adolescents and Young Adults Have Been Comparable To Younger Children: A Study From The CIBMTR. <i>Blood</i> , 2013, 122, 554-554.	0.6	8
151	ASCO Core Values. <i>Journal of Clinical Oncology</i> , 2006, 24, 5780-5782.	0.8	7
152	Three Steps Toward a More Sustainable Path for Targeted Cancer Drugs. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 2167.	3.8	7
153	Rethinking ethical oversight in the era of the learning health system. <i>Healthcare</i> , 2020, 8, 100462.	0.6	7
154	The limits of acceptable political influence over the FDA. <i>Nature Medicine</i> , 2021, 27, 188-190.	15.2	7
155	Chronic Disseminated Intravascular Coagulation and Childhood-Onset Skin Necrosis Resulting From Homozygosity for a Protein C Cla Domain Mutation, Arg15Trp. <i>Journal of Pediatric Hematology/Oncology</i> , 2002, 24, 685-688.	0.3	6
156	Investigator Experiences and Attitudes About Research With Biospecimens. <i>Journal of Empirical Research on Human Research Ethics</i> , 2015, 10, 449-456.	0.6	6
157	Pay-to-Participate Trials and Vulnerabilities in Research Ethics Oversight. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1553.	3.8	6
158	Evidence, Errors, and Ethics. <i>Perspectives in Biology and Medicine</i> , 2014, 57, 299-307.	0.3	5
159	From Sequence Data to Returnable Results: Ethical Issues in Variant Calling and Interpretation. <i>Genetic Testing and Molecular Biomarkers</i> , 2017, 21, 178-183.	0.3	5
160	Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach. <i>Trials</i> , 2017, 18, 474.	0.7	5
161	Beyond financial conflicts of interest: Institutional oversight of faculty consulting agreements at schools of medicine and public health. <i>PLoS ONE</i> , 2018, 13, e0203179.	1.1	5
162	Implementing cost transparency in oncology: A qualitative study of barriers, facilitators, and patient preferences.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6597-6597.	0.8	5

#	ARTICLE	IF	CITATIONS
163	How neonatologists use genetic testing: findings from a national survey. <i>Journal of Perinatology</i> , 2022, 42, 260-261.	0.9	5
164	Institutional Oversight of Faculty-Industry Consulting Relationships in U.S. Medical Schools: A Delphi Study. <i>Journal of Law, Medicine and Ethics</i> , 2015, 43, 383-96.	0.4	5
165	Deliberation and the Life Cycle of Informed Consent. <i>Hastings Center Report</i> , 2014, 44, 33-35.	0.7	4
166	Child and Parent Understanding of Clinical Trials: The Semi-Structured Comprehension Interview. <i>AJOB Empirical Bioethics</i> , 2015, 6, 23-32.	0.8	4
167	Physicians and Insider Trading. <i>JAMA Internal Medicine</i> , 2015, 175, 1955.	2.6	4
168	A Flawed Revision of the Common Rule. <i>Annals of Internal Medicine</i> , 2016, 165, 143.	2.0	4
169	Ethics and the Underreporting of Research Biopsy Findings in Clinical Trials. <i>JAMA Oncology</i> , 2018, 4, 1041.	3.4	4
170	The Importance of Engaging Children in Research Decision-Making: A Preliminary Mixed-Methods Study. <i>Ethics &amp; Human Research</i> , 2020, 42, 12-20.	0.5	4
171	Differences in Medical Decision Making in Adult and Pediatric Hematopoietic Stem Cell Transplantation (HCT). <i>Blood</i> , 2006, 108, 74-74.	0.6	4
172	Public dialogue and the boundaries of moral community. <i>Journal of Clinical Ethics</i> , 2003, 14, 101-8.	0.1	4
173	The Challenge of Research on Ethics Education. <i>American Journal of Bioethics</i> , 2008, 8, 12-13.	0.5	3
174	Procedure-specific consent is the norm in United States intensive care units. <i>Intensive Care Medicine</i> , 2016, 42, 1637-1638.	3.9	3
175	Will my child do better if she enrolls in a clinical trial?. <i>Cancer</i> , 2018, 124, 3965-3968.	2.0	3
176	Informed Consent and the Role of the Treating Physician. <i>New England Journal of Medicine</i> , 2018, 379, e25.	13.9	3
177	Response to Open Peer Commentaries: When Is It Ethical for Physician-Investigators to Seek Consent From Their Own Patients?. <i>American Journal of Bioethics</i> , 2019, 19, W3-W4.	0.5	3
178	Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR). <i>Blood</i> , 2013, 122, 1687-1687.	0.6	3
179	The Critical Role of Population-Based Epidemiology in Cost-Effectiveness Research. <i>Pediatrics</i> , 2000, 105, 862-863.	1.0	2
180	Costs and Respiratory Syncytial Virus. <i>Pediatrics</i> , 2001, 107, 608-609.	1.0	2

#	ARTICLE	IF	CITATIONS
181	Case Study: Informed Consent from the Doctor?. Hastings Center Report, 2004, 34, 12.	0.7	2
182	Framing the Benefits of Cancer Clinical Trials. JAMA Pediatrics, 2010, 164, 293.	3.6	2
183	Knowledge of Pediatric Ethics: Results of a Survey of Pediatric Ethics Consultants. AJOB Empirical Bioethics, 2015, 6, 19-30.	0.8	2
184	Studying Effects of Medical Treatments: Randomized Clinical Trials and the Alternatives. Journal of Law, Medicine and Ethics, 2017, 45, 375-381.	0.4	2
185	The Multidimensional Illness Severity Questionnaire: Preliminary evaluation of a brief parent-reported measure of illness severity. Journal of Paediatrics and Child Health, 2019, 55, 1241-1246.	0.4	2
186	Emergency Approvals for COVID-19: Evolving Impact on Obligations to Patients in Clinical Care and Research. Annals of Internal Medicine, 2021, 174, 256-257.	2.0	2
187	Patients' roles in governance of learning: Results from a qualitative study of 16 learning healthcare systems. Learning Health Systems, 2022, 6, e10269.	1.1	2
188	Prescription Requirements and Patient Autonomy: Considering an Over-the-Counter Default. Hastings Center Report, 2020, 50, 15-26.	0.7	2
189	Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. Blood, 2010, 116, 224-224.	0.6	2
190	Performance of genomic data strategies for cancer precision medicine across distinct contexts and ethnicities.. Journal of Clinical Oncology, 2016, 34, 1500-1500.	0.8	2
191	Dana-Farber Cancer Institute Ethics Rounds: Life-Threatening Illness and the Desire to Adopt. Kennedy Institute of Ethics Journal, 2005, 15, 385-393.	0.3	1
192	Information Disclosure and the Physician Payments Sunshine Act-Reply. JAMA - Journal of the American Medical Association, 2011, 306, 1087-1088.	3.8	1
193	Ethical Testing of Experimental Ebola Treatments-Reply. JAMA - Journal of the American Medical Association, 2015, 313, 422.	3.8	1
194	Trials Infrastructure as Good Old-Fashioned Health System Strengthening. American Journal of Bioethics, 2016, 16, W3-W5.	0.5	1
195	The Role of Patient Perspectives in Clinical Research Ethics and Policy: Response to Open Peer Commentaries on "Patient Perspectives on the Learning Health System". American Journal of Bioethics, 2016, 16, W7-W9.	0.5	1
196	Limits to research risks. , 2012, , 36-48.		1
197	Cancer patients'™ preferences for return of somatic and germline whole-exome sequencing results: Data from the CANSEQ study.. Journal of Clinical Oncology, 2014, 32, 1535-1535.	0.8	1
198	Low health literacy and its correlates among allogeneic bone marrow transplant recipients.. Journal of Clinical Oncology, 2014, 32, e17565-e17565.	0.8	1

#	ARTICLE	IF	CITATIONS
199	Deliberations of a precision medicine tumor board.. Journal of Clinical Oncology, 2016, 34, e13005-e13005.	0.8	1
200	Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation. JCO Oncology Practice, 2022, , OP2100049.	1.4	1
201	Paying for Tissue: Net Benefitsâ€™ Response. Science, 2012, 337, 1293-1293.	6.0	0
202	RE: Meta-analysis of the Relationship Between Dose and Benefit in Phase I Targeted Agent Trials. Journal of the National Cancer Institute, 2013, 105, 993-993.	3.0	0
203	Patient-Physician Relationship in the Age of Expanded Access to Informationâ€™Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1633.	3.8	0
204	Challenges in Research on Suicide Preventionâ€™Reply. JAMA - Journal of the American Medical Association, 2019, 321, 1105.	3.8	0
205	Historical trends in health care-related financial holdings among members of Congress. PLoS ONE, 2021, 16, e0253624.	1.1	0
206	Family Cord Blood Banking: Experience and Views of Pediatric Hematopoietic Stem Cell Transplant Physicians.. Blood, 2004, 104, 3323-3323.	0.6	0
207	Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 3509-3509.	0.6	0
208	Benefit in phase 1 oncology trials. , 2012, , 131-143.		0
209	Equipose and the Dilemma of Randomized Clinical Trials. , 2012, , 231-240.		0
210	Evaluating the therapeutic misconception. , 2012, , 243-255.		0
211	Abstract 2570: An integrated germline analysis platform for comprehensive clinical cancer genomics.. , 2013, , .		0
212	Assigning clinical meaning to somatic and germline whole exome sequencing data to guide cancer precision medicine.. Journal of Clinical Oncology, 2016, 34, 11565-11565.	0.8	0
213	Knowledge of regulations governing pediatric research: a pilot study. IRB: Ethics & Human Research, 2008, 30, 1-7.	0.8	0